biostudies-literatureSeftel MDHRSA/DHHSNational Cancer Institute (NCI)National Heart, Lung and Blood Institute (NHLBI)NCINHLBI NIH HHS*Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, IncNCI NIH HHSNational Cancer Institute (NCI) (to SES)PHS HHSOffice of Naval Researchthe National Institute of Allergy and Infectious Diseases (NIAID)322-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC4764423biostudies-literatureUnknown91(3)For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo American journal of hematologyPediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.PMC4764423T32 CA009515P01CA068484 (The DFCI ALL Consortium trials in younger adults)P30 CA008748U24-CA076518Grant/Cooperative Agreement 5U10HL069294P01 CA068484N00014-13-1-0039N00014-14-1-0028HHSH250201200016C with Health Resources and Services AdministrationU10 HL069294HHSH250201200016CU24 CA0765185U10HL069294Public Health Service Grant/Cooperative Agreement U24-CA076518 (CIBMTR)Wang HLSallan SEZhang MJBergeron JLazarus HMSeftel MDCouban SFreytes COSaber WTallman MSWoolfrey AEAcute Leukemia Committee of the CIBMTR and the Dana Farber ALL ConsortiumDeAngelo DJKharfan-Dabaja MASoiffer RNeuberg DHamadani MPaulson KNishihori TWeisdorf DJBallen KKfalsePediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo 2016-01-01T00:00:00Z2016 Mar2025-04-21T18:34:59.047Z2019-03-27T02:09:42ZS-EPMC47644232670114210.1002/ajh.24285